Related Experiment Video
Updated: Dec 26, 2025

Histological Quantification to Determine Lung Fungal Burden in Experimental Aspergillosis
Published on: March 9, 2018
The potency of luliconazole against clinical and environmental Aspergillus nigri complex
Sahar Hivary1, Mahnaz Fatahinia1,2, Marzieh Halvaeezadeh1
1Department of Medical Mycology, School of Medicine, Ahvaz Jundishapur University of Medical Sciences, Ahvaz, Iran.
Background And Objectives:
Black Aspergillus strains including, Aspergillus niger and A. tubingensis, are the most cause of otomycosis with worldwide distribution. Although, amphotericin B was a Gold standard for the treatment of invasive fungal infection for several decades, it gradually replaced by fluconazole and /or voriconazole. Moreover, luliconazole, appears to offer the best potential for in vitro activity against black Aspergillus strains. The aim of the present study was to compare the in vitro activity luliconazole, with commonly used antifungals against clinical and environmental strains of black Aspergillus.
Materials And Methods:
Sixty seven (37 clinical and 30 environmental) strains of black Aspergillus were identified using morphological and molecular technique (β-Tubulin gene). In addition, antifungal susceptibility test was applied according to CLSI M38 A2. The results were reported as minimum inhibitory concentration (MIC) or minimum effective concentration (MEC) range, MIC50 or MEC50, MIC90 or MEC90 and MIC geometric (GM) or MECGM.
Results:
Aspergillus niger was the common isolate followed by, A. tubingensis in both clinical and environmental strains. The lowest MIC range, MIC50, MIC90, and MICGM was attributed to luliconazole in clinical strains. The highest resistant rate was found in amphotericin B for both clinical (86.5%) and environmental (96.7%) strains whereas 54.1% of clinical and 30% of environmental isolates were resistant to caspofungin. Clinical strains of Aspergillus were more sensitive to voriconazole (86.7%) than environmental strains (70.3%). On the other hand, 83.8% of clinical and 70% of environmental isolates were resistant to posaconazole.
Conclusion:
Luliconazole versus amphotericin B, voriconazole, posaconazole and caspofungin is a potent antifungal for Aspergillus Nigri complex. The in vitro extremely antifungal efficacy against black Aspergillus strains of luliconazole, is different from those of other used antifungals.
Insights
Luliconazole demonstrates superior in vitro antifungal activity against black Aspergillus strains, including Aspergillus niger, compared to traditional antifungals like amphotericin B. This finding highlights luliconazole
Area of Science:
- Medical Mycology
- Antimicrobial Resistance
- Fungal Pathogenesis
Background:
- Black Aspergillus species, including Aspergillus niger and A. tubingensis, are prevalent causes of otomycosis globally.
- While amphotericin B was a historical standard, fluconazole and voriconazole are now commonly used for invasive fungal infections.
- Luliconazole shows promising in vitro activity against black Aspergillus.
Purpose of the Study:
- To compare the in vitro antifungal activity of luliconazole against clinical and environmental black Aspergillus strains.
- To evaluate the efficacy of luliconazole relative to established antifungals such as amphotericin B, fluconazole, voriconazole, posaconazole, and caspofungin.
Main Methods:
- Identification of 67 black Aspergillus strains (37 clinical, 30 environmental) using morphological and molecular (β-Tubulin gene) techniques.
- Antifungal susceptibility testing performed according to CLSI M38 A2 guidelines.
- Results reported as minimum inhibitory concentration (MIC) or minimum effective concentration (MEC) values, including MIC50, MIC90, and geometric mean (GM).
Main Results:
- Aspergillus niger was the most frequently isolated species, followed by A. tubingensis.
- Luliconazole exhibited the lowest MIC range, MIC50, MIC90, and MICGM against clinical strains.
- High resistance rates were observed for amphotericin B (86.5% clinical, 96.7% environmental) and caspofungin (54.1% clinical, 30% environmental).
- Voriconazole showed higher sensitivity in clinical (86.7%) versus environmental (70.3%) strains.
- Posaconazole resistance was noted in 83.8% of clinical and 70% of environmental isolates.
Conclusions:
- Luliconazole is a potent antifungal agent against the Aspergillus section Nigri complex, outperforming amphotericin B, voriconazole, posaconazole, and caspofungin in vitro.
- The study demonstrates the distinct and highly effective in vitro antifungal profile of luliconazole against black Aspergillus species compared to other tested antifungals.
Related Concept Videos
Fungal Phylum Ascomycota
Antimicrobial Effectiveness
Chemical Agents for Microbial Control

